Literature DB >> 32556945

Immortalization of Mesenchymal Stromal Cells by TERT Affects Adenosine Metabolism and Impairs their Immunosuppressive Capacity.

L R Beckenkamp1, D M S da Fontoura1, V G Korb1, R P de Campos2, G R Onzi2, I C Iser1, A P S Bertoni1, J Sévigny3,4, G Lenz2, Márcia Rosângela Wink5.   

Abstract

Mesenchymal stromal cells (MSCs) are promising candidates for cell-based therapies, mainly due to their unique biological properties such as multipotency, self-renewal and trophic/immunomodulatory effects. However, clinical use has proven complex due to limitations such as high variability of MSCs preparations and high number of cells required for therapies. These challenges could be circumvented with cell immortalization through genetic manipulation, and although many studies show that such approaches are safe, little is known about changes in other biological properties and functions of MSCs. In this study, we evaluated the impact of MSCs immortalization with the TERT gene on the purinergic system, which has emerged as a key modulator in a wide variety of pathophysiological conditions. After cell immortalization, MSCs-TERT displayed similar immunophenotypic profile and differentiation potential to primary MSCs. However, analysis of gene and protein expression exposed important alterations in the purinergic signaling of in vitro cultured MSCs-TERT. Immortalized cells upregulated the CD39/NTPDase1 enzyme and downregulated CD73/NT5E and adenosine deaminase (ADA), which had a direct impact on their nucleotide/nucleoside metabolism profile. Despite these alterations, adenosine did not accumulate in the extracellular space, due to increased uptake. MSCs-TERT cells presented an impaired in vitro immunosuppressive potential, as observed in an assay of co-culture with lymphocytes. Therefore, our data suggest that MSCs-TERT have altered expression of key enzymes of the extracellular nucleotides/nucleoside control, which altered key characteristics of these cells and can potentially change their therapeutic effects in tissue engineering in regenerative medicine.

Entities:  

Keywords:  Adenosine; Adenosine deaminase; CD39 / NTPDase1; CD73 / NT5E; Immunosuppression; Mesenchymal stromal cells; Purinergic signaling; TERT

Mesh:

Substances:

Year:  2020        PMID: 32556945     DOI: 10.1007/s12015-020-09986-5

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  3 in total

1.  Transgenic Immortalization of Human Dermal Fibroblasts Mediated Through the MicroRNA/SIRT1 Pathway.

Authors:  Wilasinee Promjantuek; Nipha Chaicharoenaudomrung; Ruchee Phonchai; Phongsakorn Kunhorm; Parinya Noisa
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  BDNF-Overexpressing Engineered Mesenchymal Stem Cells Enhances Their Therapeutic Efficacy against Severe Neonatal Hypoxic Ischemic Brain Injury.

Authors:  So Yoon Ahn; Dong Kyung Sung; Yun Sil Chang; Se In Sung; Young Eun Kim; Hyo-Jin Kim; Soon Min Lee; Won Soon Park
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

3.  PSME4 Degrades Acetylated YAP1 in the Nucleus of Mesenchymal Stem Cells.

Authors:  Yong Sook Kim; Mira Kim; Dong Im Cho; Soo Yeon Lim; Ju Hee Jun; Mi Ra Kim; Bo Gyeong Kang; Gwang Hyeon Eom; Gaeun Kang; Somy Yoon; Youngkeun Ahn
Journal:  Pharmaceutics       Date:  2022-08-09       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.